ProCE Banner Activity

CME

Myelofibrosis and Polycythemia Vera: Current and Emerging Treatment Options

Text Module

In this interactive, CME/CE-certified module, Srdan Verstovsek, MD, PhD, provides expert perspectives on key data informing optimal treatment strategies for MF and PV.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: May 08, 2017

Expiration: December 31, 2024

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

Incyte

Target Audience

This program is intended for physicians, registered nurses, and other healthcare providers who care for patients with myeloproliferative neoplasms.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest clinical findings in the treatment of patients with myelofibrosis
  • Choose optimal current treatment strategies for patients with polycythemia vera
  • Evaluate the clinical data on promising agents and combination regimens likely to improve outcomes for patients with myeloproliferative neoplasms

Faculty Disclosure

Primary Author

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that his institution has received funds for the conduct of clinical studies that he participated in from AstraZeneca, Blueprint Medicines, Bristol-Myers Squibb, Celgene, CTI BioPharma, Galena BioPharma, Genentech, Geron, Gilead Sciences, Incyte, Lilly Oncology, NS Pharma, Pfizer, Promedior, Roche, and Seattle Genetics.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 08, 2017, through December 31, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence in applying current and emerging treatments in the care of patients with myelofibrosis or polycythemia vera.